My main takeaways:
"However, we observed decreases in
My main takeaways:
"However, we observed decreases in circulating tumor DNA in 100% of patients, which indicated potent anti-tumor activity with just leronlimab and the backbone regimen, even at the lowest dose of 350 mg."
"In discussions with potential big pharma partners, one of the things they asked for was prospective confirmation that leronlimab would induce PDL1 and turn cold tumors hot — enabling treatment with an immune checkpoint inhibitor in a tumor with little to no immune cell infiltration."
"Patients were also calling us wanting access."
"It turns out that lower dose is demonstrating encouraging activity in CRC, and it's unclear whether the higher dose is going to be better. So even if you think you know, you might not."
"The ctDNA data that we've generated is preliminary, but no one has ever seen anything quite like it in terms of a 70% decrease in at week 2. It's not enough for the FDA. And it's not quite enough yet for a partnership, but every oncologist I show that data seems pretty impressed. We now have quite a few academic oncologists come to us now proposing their own investigator-initiated studies. When you add this early evidence of biologic activity with a benign safety profile and potential relevance throughout solid tumor oncology, you have a rather amazing story."
This, imo, is much better than the best PR we can get ...
30
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...
Continue Reading
Premium Racing Takes a New Spin Scratch the surface of a tire-obsessed market, and you'll find Superteam Wheels making a calculated leap. Their new premium sub-brand, MATIC, isn't just fluff—it shows a serious attempt to impress those who’d rather cut corners on a track than a spreadsheet. Introducing the MATIC S68—buttery smooth, pitch-perfect, and undeniably...
Continue Reading
A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...
Continue Reading
Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....
Continue Reading
Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...
Continue Reading
Preparing for the Real Estate Rollercoaster Getting ready to sell your home? Let's cut through the noise and get right into the nitty-gritty with Jodi Kallus, a seasoned real estate pro with Summit Realtors. The first step ain't just about slapping a ‘For Sale’ sign on your front lawn. It's about laying down a plan that's as solid as the foundation of the house you're...
Continue Reading
An Investor's Wake-Up Call: Beta Bionics Lawsuit Folks, if you've got skin in the game with Beta Bionics (NASDAQ: BBNX), there's a storm on the horizon. We're talking big legal guns out and aimed at Beta Bionics with that class action suit looming. If you sunk some serious dough between July 30, 2025, and February 24, 2026, it's time to shake up and assess your losses....
Continue Reading
Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...
Continue Reading
Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...
Continue Reading
Blockchain is Not Just for Bitcoin Anymore Who would've thought, right? Blockchain's no longer just the playground for cryptocurrency enthusiasts. Today, it's making waves in the media and entertainment sector. Latest numbers from Credence Research have this market set to explode from $748 million in 2025 to a jaw-dropping $3.33 billion by 2035. Yeah, folks, that's a...
Continue Reading
Top 5 Most Recently Viewed Articles
oToBrite and SINTRONES Collaborate on Revolutionary Technology oToBrite is making waves in the tech industry by teaming up with SINTRONES to present their groundbreaking AI depth vision application at COMPUTEX. This innovative showcase uses only a single automotive camera module, setting a new standard for depth imaging and distance estimation. The system’s potential...
Continue Reading
Octopus AIM VCT 2 Engages in Strategic Share Buyback Octopus AIM VCT 2 plc has made a noteworthy move recently by purchasing its own securities, reflecting its proactive approach to managing its capital structure. This strategic decision involved the cancellation of 640,016 ordinary shares, each with a nominal value of 0.01p, executed at a price of 36.6831p per share....
Continue Reading
Epsium Enterprise Limited Announces Financial Performance Epsium Enterprise Limited (NASDAQ: EPSM) has unveiled its unaudited financial results for the six-month period ended June 30, 2025, reflecting a committed approach to growth and fiscal responsibility. As a notable importer and distributor of premium alcoholic beverages, the company's robust financial foundation...
Continue Reading
ACE Money Transfer Partners with Alipay for Better Services In a significant development in the world of remittances, ACE Money Transfer has announced that it is partnering with Alipay, one of the leading digital payment platforms globally. This collaboration aims to enhance the efficiency and security of money transfers, particularly benefiting the Chinese diaspora which...
Continue Reading
Hanmi Pharmaceutical Launches Aditams in Mexico Hanmi Pharmaceutical Begins Local Sales of Aditams with Partner Laboratorios Silanes Hanmi Pharmaceutical has successfully launched Aditams, its innovative urological product, in the Mexican market. This product is being introduced in collaboration with Laboratorios Silanes, a prominent player in the local pharmaceutical...
Continue Reading